Following a stroke, antibodies that inhibit the signaling molecule Nogo-A can help repair blood vessels in the affected brain regions. This also promotes the regaining of motor functions, researchers have shown in a mouse model. The study opens up new avenues for treatment.
Each year, around 16,000 people in Switzerland and 15 million people worldwide suffer a stroke. Two thirds of those affected die or remain in permanent need of care due to the brain's limited capacity to regenerate damaged tissue and neural circuits. At present, despite intensive research efforts only few medical therapy options are available that reduce the serious consequences after cerebral stroke.
A promising new approach to promote the recovery of physiological functions aims to repair the system of blood vessels in the affected brain regions. The system supplies the injured tissue with oxygen and key nutrients. In people who have suffered a stroke, this repair process is inhibited by a number of mechanisms. A few years ago, the research group used a mouse model to, among other things, show that the signaling molecule Nogo-A not only reduces the growth of nerve fibers, but also regulates blood vessel sprouting in the brain and could thus also inhibit their repair.
In a new study with mice, the researchers genetically deactivated the Nogo-A molecule or one of its corresponding receptors S1PR2. The blood vessels in these mice showed improved regenerative capacity, and they recovered affected motor skills better than those of the mice in the control group. These findings were reproduced in a therapeutic approach using anti-Nogo-A antibodies in mice following a stroke, which too led to the re-formation of a robust and functional vascular network around the affected brain regions. "The nervous system of the treated mice showed better recovery and their motor functions were less affected, which we ascribe to vascular regeneration," says first author.
Previous experimental efforts to enhance vessel growth have almost exclusively focused on vascular growth factor supplementation, an approach that has been shown to be clinically unviable due to adverse side effects such as increased risk of hemorrhage. "Our findings provide a promising alternative approach to treating stroke patients," says the author, "not least since anti-Nogo-A antibodies are already being used in clinical testing for spinal cord injuries."
https://www.pnas.org/content/early/2019/06/18/1905309116
Promoting vascular repair following stroke
- 1,411 views
- Added
Edited
Latest News
Zone 2 hepatocytes help in maintenance and regeneration of liver
Nanobody-mediated control of gene expression and epigenetic memory
Re-engineering Botox for Multiple Functions
New signaling pathway in neurons
Mother's diet boosts immune systems of premature infants
Other Top Stories
Electrophysiological signature of wandering brain
How brain circuitry develops spontaneously
Comparing low-fat, plant-based diet to low-carb, animal-based diet
The brain region responsible for self-bias in memory
Exosomal delivery of drugs to reduce pre-term birth
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
Nanobody-mediated control of gene expression and epigenetic memory
Interaction of 7SK with the Smn complex modulates snRNP production
Maternal aryl hydrocarbon receptor activation protects newborns against necrotizing enterocolitis
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum
Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemica…
Presentations
Botulinum toxin
Bioplar Disorder
G-Protein-Coupled Receptors
Mood Disorders
Mitochondrial DNA
Posters
ASCO-2020-CENTRAL NERVOUS SYSTEM TUMORS
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–IMMUNOTHERAPY
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–MOLECULARLY TARGETED AGENTS AND TUMOR BIOLOGY
ASCO-2020-CANCER PREVENTION, RISK REDUCTION, AND GENETICS
ASCO-2020-BREAST CANCER–METASTATIC